Apollo Hospitals Announces ₹250 Crore Investment in Advanced Cancer Treatment

Apollo Hospitals Enterprise Ltd announced on Tuesday, March 4, its plans to set up a state-of-the-art oncology centre featuring India’s first Proteus One proton system. The company will invest ₹250 crore over the next three years to establish the facility in Hyderabad, which is expected to be operational by FY2028.

Expansion of Proton Therapy Capacity

The new facility aims to enhance Apollo’s existing proton therapy capacity, which currently treats over 500 patients annually at its Chennai centre, designed for 850 patients. With the Hyderabad expansion, Apollo will be able to treat an additional 350 patients every year. The investment for this initiative will be funded through internal accruals.

Collaboration with Ion Beam Applications (IBA)

Apollo Hospitals has partnered with Ion Beam Applications (IBA), a global leader in proton beam therapy solutions, to introduce the Proteus One system in India. Apollo first pioneered proton therapy in 2019 at its Chennai centre, making it the only such facility in South Asia and the Middle East.

Benefits of Proton Therapy for Cancer Treatment

Proton therapy is a highly advanced form of radiation treatment, primarily used for complex cancers, including central nervous system, head and neck tumours, paediatric, and urological cancers. The Proteus One system will offer cutting-edge precision, ensuring superior clinical outcomes and minimizing side effects for patients.

Leadership’s Vision for the Project

Dr Prathap C Reddy, Founder-Chairman of Apollo Hospitals Enterprise Ltd, emphasized the significance of this development, stating, “The addition of Proteus One to our Apollo Proton Cancer Centres further solidifies our position as a global leader in proton therapy. This next-generation technology will allow us to achieve superior clinical outcomes and significantly improve the quality of life for cancer patients in India and beyond.”

Stock Performance

On March 05, 2025, Apollo Hospitals share price traded 0.69% lower at ₹6149.05 at 9:19 AM (IST). Apollo Hospitals’s share price reached a 52-week high of ₹7,545.10 on November 18, 2024, and a 52-week low of ₹5,690.80 on June 04, 2024. As per BSE, the total traded volume for the stock stood at 147 shares with a turnover of ₹9.10 lakhs.

At the current price, Apollo Hospitals shares are trading at a price-to-earnings (P/E) ratio of 73.81x, based on its trailing 12-month earnings per share (EPS) of ₹83.58, and a price-to-book (P/B) ratio of 10.83, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.